Search results
Alvesco: Side effects and what to do about them
Medical News Today· 2 days agoAlvesco (ciclesonide) is a brand-name inhaled corticosteroid that’s prescribed for asthma in adults and certain children. As with other drugs, Alvesco...
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Zacks via Yahoo Finance· 17 hours agoThe late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with...
Tyrvaya side effects: What they are and how to manage them
Medical News Today· 1 day agoTyrvaya is a prescription drug to treat dry eye disease. Learn about the common, mild, and serious...
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
BioPharma Dive via Yahoo Finance· 3 days ago“I just feel very convinced that I had to vote no,” said one member of the committee, which was...
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
Motley Fool via Yahoo Finance· 22 hours agoThe takeaway is that these are pretty good results. All of that means the probability of Novo...
Azstarys cost 2024: Coupons and more
Medical News Today· 2 days agoAzstarys (serdexmethylphenidate/dexmethylphenidate) is a brand-name oral capsule prescribed for ADHD in adults and some children. The cost of the drug,...
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Motley Fool via Yahoo Finance· 4 days agoThe 10 stocks that made the cut could produce monster returns in the coming years. Consider when...
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Zacks via Yahoo Finance· 3 days agoData from a late-stage study shows that transfusion-dependent thalassemia patients who received...
Gene therapy and employee benefits: from science fiction to medical reality
BenefitsPRO· 4 days agoAt the rate research and approvals have been accelerating, the 2020s may be remembered as the decade...
Ecstasy’s path to approval for PTSD treatment faces doubts from FDA staff
Washington Post via Yahoo News· 6 days agoThe U.S. Food and Drug Administration released an analysis Friday that raised extensive questions...